JP2024508746A - ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法 - Google Patents

４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法 Download PDF

Info

Publication number
JP2024508746A
JP2024508746A JP2023549549A JP2023549549A JP2024508746A JP 2024508746 A JP2024508746 A JP 2024508746A JP 2023549549 A JP2023549549 A JP 2023549549A JP 2023549549 A JP2023549549 A JP 2023549549A JP 2024508746 A JP2024508746 A JP 2024508746A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antigen
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508746A5 (enExample
Inventor
レオナルド ビアンヴニュ，デイビッド
Original Assignee
アプティーボ リサーチ アンド デベロップメント エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプティーボ リサーチ アンド デベロップメント エルエルシー filed Critical アプティーボ リサーチ アンド デベロップメント エルエルシー
Publication of JP2024508746A publication Critical patent/JP2024508746A/ja
Publication of JP2024508746A5 publication Critical patent/JP2024508746A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023549549A 2021-02-17 2022-02-17 ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法 Pending JP2024508746A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150475P 2021-02-17 2021-02-17
US63/150,475 2021-02-17
PCT/US2022/016776 WO2022178114A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2024508746A true JP2024508746A (ja) 2024-02-28
JP2024508746A5 JP2024508746A5 (enExample) 2025-02-21

Family

ID=80738990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549549A Pending JP2024508746A (ja) 2021-02-17 2022-02-17 ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法

Country Status (8)

Country Link
US (1) US20240150483A1 (enExample)
EP (1) EP4294843A1 (enExample)
JP (1) JP2024508746A (enExample)
KR (1) KR20230167025A (enExample)
CN (1) CN117203236A (enExample)
AU (1) AU2022223692A1 (enExample)
CA (1) CA3208339A1 (enExample)
WO (1) WO2022178114A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
WO2020011966A1 (en) * 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
JP2020510079A (ja) * 2017-03-16 2020-04-02 エルジー・ケム・リミテッド 抗ＴＮＦα抗体の液状製剤
JP2022545368A (ja) * 2019-08-12 2022-10-27 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
BR112021013571A2 (pt) * 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
JP2020510079A (ja) * 2017-03-16 2020-04-02 エルジー・ケム・リミテッド 抗ＴＮＦα抗体の液状製剤
WO2020011966A1 (en) * 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
JP2022545368A (ja) * 2019-08-12 2022-10-27 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Dual-targeting of 4-1BB and OX40 with anADAPTIR bispecific antibody enhances anti-tumor responses to", JOURNAL FOR IMMUNO THERAPY OF CANCER, vol. vol. 8, Supplement 3, JPN6025053785, 2020, pages 379 - 380, ISSN: 0005765853 *
CANCER IMMUNOLOGY RESEARCH, vol. 8, JPN6025053782, 2020, pages 781 - 793, ISSN: 0005765854 *

Also Published As

Publication number Publication date
AU2022223692A1 (en) 2023-09-21
KR20230167025A (ko) 2023-12-07
CN117203236A (zh) 2023-12-08
CA3208339A1 (en) 2022-08-25
WO2022178114A1 (en) 2022-08-25
EP4294843A1 (en) 2023-12-27
US20240150483A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP7465382B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
CN108463245A (zh) 具有修饰的j链的结合分子
BR112019016104A2 (pt) composição farmacêutica de baixo ph compreendendo construtos de anticorpo que empregam células t
JP2023532129A (ja) Ｂｃｍａに結合する多重特異性抗体
WO2013043071A1 (en) Modified albumin-binding domains and uses thereof to improve pharmacokinetics
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
KR20230110303A (ko) 폴레이트 수용체 알파에 결합하는 중쇄 항체
JP2024508746A (ja) ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法
WO2024231251A1 (en) Anti-il1rap antibodies
JP7691138B2 (ja) ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
WO2024165403A1 (en) Anti-cea antibodies
KR20250155046A (ko) 다작용성 항체
KR20240112342A (ko) B7-h4 항체 및 항-b7-h4 항체/il-15 융합 단백질
JP2023551907A (ja) 腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法
EP4185388A1 (en) A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
HK40036534A (en) Heavy chain antibodies binding to cd22
HK40022776A (en) Anti-bcma heavy chain-only antibodies
BR112018015715B1 (pt) Construto de anticorpo de cadeia única, seu uso, composição farmacêutica e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260108